ALRN – aileron therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

ALRN

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/15

07:07 am

alrn

Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]

High Report

Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]

Report

11/14

04:21 pm

alrn

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

High Report

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Report

11/14

04:15 pm

alrn

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

High Report

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Report

11/13

01:26 pm

alrn

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]

Low Report

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]

Report

11/13

07:00 am

alrn

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Medium Report

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Report

10/31

07:30 am

alrn

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Medium Report

Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

Report

10/12

09:00 am

alrn

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

Low Report

Report

9/23

07:30 am

alrn

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Medium Report

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

Report

Date

Time

Symbol

Company Name

Action

%Chg

Date

Time

Action

From

Firm

Impact

%Chg

Date

Time

Symbol

Headline

Impact

11/14

04:10 pm

alrn

Form 8-K Aileron Therapeutics, For: Nov 14

High Report

Form 8-K Aileron Therapeutics, For: Nov 14

Report

11/14

04:05 pm

alrn

Form 10-Q Aileron Therapeutics, For: Sep 30

High Report

Form 10-Q Aileron Therapeutics, For: Sep 30

Report

11/5

05:18 pm

alrn

Form SCHEDULE 13G/A Aileron Therapeutics, Filed by: UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO

Low Report

Form SCHEDULE 13G/A Aileron Therapeutics, Filed by: UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO

Report

8/22

04:09 pm

alrn

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Aivado Manuel

Medium Report

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Aivado Manuel

Report

8/22

04:07 pm

alrn

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Fairey William

Medium Report

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Fairey William

Report

8/22

04:07 pm

alrn

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: VON RICKENBACH JOSEF H

Medium Report

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: VON RICKENBACH JOSEF H

Report

8/22

04:06 pm

alrn

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Musso Alan A

Medium Report

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Musso Alan A

Report

8/22

04:06 pm

alrn

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Ambros Reinhard J.

Medium Report

Form 4 Aileron Therapeutics, For: Aug 20 Filed by: Ambros Reinhard J.

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.